Pharmafile Logo
Pharmafocus logo
Advanced Search

Allergan

Showing 15 posts of 142 posts found.

allergan

Allergan says its double chin correction therapy Belkyra gets positive opinion from Swedish regulators

July 4, 2016
Research and Development, Sales and Marketing Allergan, Belkyra, Botox, EU, Sweden, double chin, drug trial

Botox maker Allergan (NYSE: AGN) said it has received a positive opinion from the Swedish Medical Products Agency for its …

News
teva_copy

Mayne Pharma to buy a portfolio of Teva’s generic drugs for $652 million

June 29, 2016
Research and Development, Sales and Marketing Allergan, Deals, Mayne Pharma, Teva, generics, merger and acquisition

Australia’s Mayne Pharma Group Ltd (ASX: MYX) said it will acquire US generic products from Israel-based drugmaker Teva Pharmaceuticals (NYSE: …

News
allergan

FDA approves expanded label for Allergan’s Avycaz

June 24, 2016
Medical Communications, Research and Development, Sales and Marketing Allergan, Avycaz, FDA, expanded label

Allergan (NYSE: FDA) has announced that the US Food and Drug Administration (FDA) has approved its supplemental new drug application …

News
teva_copy

Impax to acquire Teva, Allergan generic drugs for $586 million

June 22, 2016
Research and Development, Sales and Marketing Allergan, Impax, Teva, generics

Impax Laboratories (NASDAQ: IPXL) has announced that it has entered into agreements with Teva and affiliates of Allergan to acquire …

News
allergan

FDA approves Allergan hypertension fixed-dose combo, Byvalson

June 7, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Allergan, FDA, US, angiotensin ii, approval, beta blocker, byvalson, hypertension, nebivolol, valsartan

Allergan has announced that the US Food and Drug Administration (FDA) has approved its fixed-dose combination, Byvalson (nebivolol and valsartan), …

News
allergan

Allergan’s chronic eye disease treatment meets endpoints in pivotal trials

May 17, 2016
Manufacturing and Production, Sales and Marketing Allergan, FDA, chronic eye disease

Allergan has announced positive top line results from two pivotal late-stage trials for the first and only neurostimulation device for …

News
stocks1

Weekly Movers: Teva, Midatech, Allergan…

May 16, 2016
Research and Development, Sales and Marketing Allergan, Ariad Pharmaceuticals, Lundbeck, Midatech Pharma, Stock, Teva Pharmaceutical, markets

We have hit the tail end of the earnings season and the near last batch of movers follow result pronouncements …

Feature
allergan

Allergan to buy back $10 billion of stock, Q1 earnings rise

May 11, 2016
Research and Development, Sales and Marketing Allergan, Buy Back, Financial, Q1, earnings, results, revenue

Botox-maker Allergan (NYSE: AGN) said it plans to buy back as much as $10 billion in stock after completing the …

News
allergan

Phase III trial meets primary endpoint for Allergan’s fibroid treatment

May 9, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Allergan, fibroid, phase 3, phase III, ulipristal, ulipristal acetate, uterine fibroid

Allergan (NYSE: AGN), in collaboration with Gedeon Richter, has announced positive results from a pivotal Phase III trial evaluating the …

News
v2_crestor_10_mg

Allergan launches Crestor generic in the US

May 3, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Allergan, AstraZeneca, Crestor, FDA, FDA Approval, cholesterol, generic, patent, patent expiry, sales

Allergan has received FDA approval on the generic version of AstraZeneca’s high cholesterol drug, Crestor (rosuvastatin), and has become the …

News
allergan_waco

Allergan breaks ground on $200 million expansion at Texas site

April 26, 2016
Manufacturing and Production Allergan, doubling, expansion, eye care, facility, investment, manufacturing, size, texas, waco

Allergan (NYSE: AGN) has broken ground on a $200 million expansion at its manufacturing facility in Waco, Texas. The expansion …

News
shirelogo

Shire reassures Baxalta acquisition on track in the aftermath of Pfizer-Allergan breakup

April 7, 2016
Business Services, Sales and Marketing AbbVie, Allergan, Baxalta, Deals, Financial, Merger & Acquisition, Pfizer, Shire

Ireland-headquartered Shire Plc (LSE: SHP) has reassured its $32-billion merger deal with US-based Baxlata (NYSE: BXLT) remains on track in …

News
handshake

Allergan to partner with Heptares in Alzheimer’s disease collaboration

April 7, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Alzheimer's, Heptares, R&D, collaboration, commercialisation, h1, h4, neurological disorders, partnership, research and development, treatments

Bouncing back quickly from the collapse of the collapse of the Pfizer inversion deal, Allergan (NYSE:AGN) has announced a new …

News
pfizer_building

5 things to know about the Pfizer/Allergan inversion collapse

April 6, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 5, 5 things, Allergan, Pfizer, collapse, inversion, reasons

The end came very quickly for the Pfizer/Allergan $160 billion deal once the US Treasury Department announced a new set …

Feature
pfizer_logo

Pfizer to call off $160 billion merger with Allergan

April 6, 2016
Business Services, Research and Development, Sales and Marketing Allergan, Pfizer, deal, legal, merger and acquisition, regulation

US pharma giant Pfizer Inc (NYSE: PFE) has decided to terminate the $160 billion merger with Botox-maker Allergan Plc (NYSE: …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023